Ozguroglu M, Sari O, Turna H
Section of Medical Oncology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:394-6. doi: 10.1111/j.1525-1438.2006.00214.x.
Paclitaxel and platinum combination is the standard chemotherapy regimen for patients with advanced epithelial ovarian cancer. The dose-limiting toxicity effects of this combination are myelosuppression and neuropathy. Herein, we report a case of a 71-year-old female with advanced epithelial ovarian cancer who developed bilateral total loss of hearing and acute renal failure related with paclitaxel- and carboplatin-based chemotherapy. Acute renal failure accompanied by complete loss of hearing in patients treated with carboplatin and paclitaxel combination has not been previously reported. This uncommon adverse effect of carboplatin and paclitaxel combination was discussed, and all the literature in English related with the toxicity of paclitaxel and carboplatin were reviewed.
紫杉醇与铂类联合是晚期上皮性卵巢癌患者的标准化疗方案。该联合方案的剂量限制性毒性作用为骨髓抑制和神经病变。在此，我们报告一例71岁晚期上皮性卵巢癌女性患者，其在接受基于紫杉醇和卡铂的化疗后出现双侧全聋及急性肾衰竭。此前尚未有关于接受卡铂和紫杉醇联合治疗的患者出现急性肾衰竭伴完全失聪的报道。本文讨论了卡铂和紫杉醇联合方案这一罕见的不良反应，并回顾了所有与紫杉醇和卡铂毒性相关的英文文献。
